Skip to main content
    A

    Anavex Life Sciences Corp (AVXL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.82
    -0.12 (-12.42%)

    Market Cap: $86.53M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anavex Life Sciences Corp (AVXL) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Anavex Life Sciences (AVXL) to earn -$0.55 per share in the fiscal year ending Sep 30, 2027. Over the last 30 days, 0 estimates for the fiscal year ending Sep 30, 2027 were revised up and 1 down. For the quarter ending Dec 31, 2026, the EPS consensus is -$0.12.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Sep 30, 2027
    -$0.55
    EPS consensus
    Next report
    Nov 23, 2026
    Estimated
    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Sep 30, 2027-$0.55-$0.55 to -$0.551

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.12-$0.12 to -$0.121

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Sep 30, 202701
    Quarter ending Dec 31, 202600

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has worsened from -$0.14.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Sep 30, 2027-$0.55-$0.14-$0.14-$0.14-$0.14N/A
    Quarter ending Dec 31, 2026-$0.12-$0.12-$0.12N/AN/AN/A

    Frequently Asked Questions About AVXL

    What is the AVXL stock forecast?

    Consensus analyst estimates put Anavex Life Sciences's EPS at -$0.55 for the fiscal year ending Sep 30, 2027.

    What EPS do analysts expect from AVXL next year?

    For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$0.55, with estimates from -$0.55 to -$0.55 from 1 analyst.

    How many analysts cover AVXL?

    1 analyst estimates EPS for Anavex Life Sciences for the fiscal year ending Sep 30, 2027.